接受免疫治疗的晚期非小细胞肺癌患者的预后因素
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
作者信息
Rocco Danilo, Della Gravara Luigi, Ragone Angela, Sapio Luigi, Naviglio Silvio, Gridelli Cesare
机构信息
Department of Pulmonary Oncology, AORN dei Colli Monaldi, 80131 Naples, Italy.
Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Naples, Italy.
出版信息
Cancers (Basel). 2023 Sep 22;15(19):4684. doi: 10.3390/cancers15194684.
Abstract
Taking into account the huge epidemiologic impact of lung cancer (in 2020, lung cancer accounted for 2,206,771 of the cases and for 1,796,144 of the cancer-related deaths, representing the second most common cancer in female patients, the most common cancer in male patients, and the second most common cancer in male and female patients) and the current lack of recommendations in terms of prognostic factors for patients selection and management, this article aims to provide an overview of the current landscape in terms of currently available immunotherapy treatments and the most promising assessed prognostic biomarkers, highlighting the current state-of-the-art and hinting at future challenges.
摘要
考虑到肺癌巨大的流行病学影响（2020年，肺癌病例达2206771例，癌症相关死亡达1796144例，是女性患者中第二常见的癌症、男性患者中最常见的癌症以及男性和女性患者中第二常见的癌症）以及目前在患者选择和管理的预后因素方面缺乏相关建议，本文旨在概述当前可用免疫治疗的现状以及最有前景的评估预后生物标志物，突出当前的技术水平并暗示未来的挑战。
相似文献
1
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.接受免疫治疗的晚期非小细胞肺癌患者的预后因素
Cancers (Basel). 2023 Sep 22;15(19):4684. doi: 10.3390/cancers15194684.
2
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
3
[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].[程序性死亡蛋白1/程序性死亡配体1抑制剂治疗转移性非小细胞肺癌患者的疗效及预后预测生物标志物的真实世界研究]
Zhonghua Zhong Liu Za Zhi. 2022 May 23;44(5):416-424. doi: 10.3760/cma.j.cn112152-20210709-00504.
4
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?肿瘤突变负荷评估作为肺癌患者免疫治疗的预测生物标志物：是否已准备好进入黄金时代？
Transl Lung Cancer Res. 2018 Dec;7(6):631-638. doi: 10.21037/tlcr.2018.08.04.
5
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
6
Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.联合生物标志物预测接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者临床结局的价值。
Clin Lung Cancer. 2021 Nov;22(6):500-509. doi: 10.1016/j.cllc.2021.03.017. Epub 2021 Mar 27.
7
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.探索基于全基因组测序的生物标志物在无法接受靶向治疗的晚期肺癌患者中进行治疗选择的成本效益。
Pharmacoeconomics. 2024 Apr;42(4):419-434. doi: 10.1007/s40273-023-01344-w. Epub 2024 Jan 9.
8
Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer.外周血生物标志物在抗 PD-1 免疫治疗非小细胞肺癌中的反应变化。
Clin Transl Oncol. 2024 Aug;26(8):1934-1943. doi: 10.1007/s12094-024-03416-5. Epub 2024 Mar 7.
9
Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.肿瘤突变负担作为晚期非小细胞肺癌中 PD-1/PD-L1 抑制的潜在生物标志物。
Target Oncol. 2020 Feb;15(1):93-100. doi: 10.1007/s11523-020-00703-3.
10
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.非小细胞肺癌中高肿瘤突变负荷与 PD-L1 表达水平相关的免疫浸润增加和 PD-L1 阻断临床获益改善的相关性。
JAMA Oncol. 2022 Aug 1;8(8):1160-1168. doi: 10.1001/jamaoncol.2022.1981.
引用本文的文献
1
Integrating Clinical and Imaging Markers for Survival Prediction in Advanced NSCLC Treated with EGFR-TKIs.整合临床和影像标志物用于预测接受表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）治疗的晚期非小细胞肺癌（NSCLC）患者的生存情况
Cancers (Basel). 2025 Aug 3;17(15):2565. doi: 10.3390/cancers17152565.
2
Real-World Data on Immune-Checkpoint Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Study.老年晚期非小细胞肺癌患者免疫检查点抑制剂的真实世界数据：一项回顾性研究。
Cancers (Basel). 2025 Jun 29;17(13):2194. doi: 10.3390/cancers17132194.
3
The influence of nutritional status, lipid profile, leptin concentration and polymorphism of genes encoding leptin and neuropeptide Y on the effectiveness of immunotherapy in advanced NSCLC patients.营养状况、血脂谱、瘦素浓度以及瘦素和神经肽 Y 编码基因多态性对晚期 NSCLC 患者免疫治疗效果的影响。
BMC Cancer. 2024 Aug 1;24(1):937. doi: 10.1186/s12885-024-12716-6.
4
Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC).肠道微生物群是非小细胞肺癌（NSCLC）免疫治疗生物标志物的新来源。
Cancers (Basel). 2024 May 9;16(10):1806. doi: 10.3390/cancers16101806.
5
The Nine-Year Survival of Patients Operated for Non-Small-Cell Lung Carcinoma in a Tertiary Centre: The Impact of the Tumour Stage and Other Patient-Related Parameters.三级中心接受手术治疗的非小细胞肺癌患者的 9 年生存情况：肿瘤分期和其他患者相关参数的影响。
Medicina (Kaunas). 2024 Feb 28;60(3):415. doi: 10.3390/medicina60030415.
6
Inhaled Medicines for Targeting Non-Small Cell Lung Cancer.用于靶向非小细胞肺癌的吸入药物。
Pharmaceutics. 2023 Dec 14;15(12):2777. doi: 10.3390/pharmaceutics15122777.
7
Gut-lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy.肠-肺轴：肠道微生物群在非小细胞肺癌免疫治疗中的作用
Front Oncol. 2023 Nov 22;13:1257515. doi: 10.3389/fonc.2023.1257515. eCollection 2023.
本文引用的文献
1
Understanding the role of the gut microbiome in gastrointestinal cancer: A review.了解肠道微生物群在胃肠道癌症中的作用：综述
Front Pharmacol. 2023 Jan 24;14:1130562. doi: 10.3389/fphar.2023.1130562. eCollection 2023.
2
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.非癌基因成瘾性转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Apr;34(4):358-376. doi: 10.1016/j.annonc.2022.12.013. Epub 2023 Jan 17.
3
Corticosteroids and Cancer Immunotherapy.皮质类固醇和癌症免疫疗法。
Clin Cancer Res. 2023 Jul 14;29(14):2580-2587. doi: 10.1158/1078-0432.CCR-22-3181.
4
Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab.中性粒细胞与淋巴细胞比值是接受派姆单抗一线免疫治疗的非小细胞肺癌患者的主要预后因素。
Cancer Diagn Progn. 2023 Jan 3;3(1):44-52. doi: 10.21873/cdp.10178. eCollection 2023 Jan-Feb.
5
The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.基线质子泵抑制剂、免疫检查点抑制剂与化疗之间的关联：一项网状Meta分析的系统评价
Cancers (Basel). 2022 Dec 31;15(1):284. doi: 10.3390/cancers15010284.
6
Tumour-infiltrating lymphocytes: from prognosis to treatment selection.肿瘤浸润淋巴细胞：从预后到治疗选择。
Br J Cancer. 2023 Feb;128(3):451-458. doi: 10.1038/s41416-022-02119-4. Epub 2022 Dec 23.
7
Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis.免疫治疗的晚期非小细胞肺癌患者的癌症恶病质：一项探索性肠道微生物群分析的观察性研究
Cancers (Basel). 2022 Nov 2;14(21):5405. doi: 10.3390/cancers14215405.
8
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.度伐利尤单抗联合或不联合替西木单抗联合化疗作为转移性非小细胞肺癌一线治疗的 III 期 POSEIDON 研究。
J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3.
9
Targeting the gut microbiota for cancer therapy.以肠道微生物群为靶点进行癌症治疗。
Nat Rev Cancer. 2022 Dec;22(12):703-722. doi: 10.1038/s41568-022-00513-x. Epub 2022 Oct 17.
10
The multiple roles of LDH in cancer.LDH 在癌症中的多重作用。
Nat Rev Clin Oncol. 2022 Dec;19(12):749-762. doi: 10.1038/s41571-022-00686-2. Epub 2022 Oct 7.
Zotero 插件